Day: January 2, 2024

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 2, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA. A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation. About Prime MedicinePrime Medicine is a leading biotechnology company dedicated...

Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening

Written by Customer Service on January 2, 2024. Posted in Public Companies.

Extensive Clinical Network and Flexible Service Model to Meet Hiring Demands in Healthcare and Other Regulated Industries INDEPENDENCE, Ohio, Jan. 02, 2024 (GLOBE NEWSWIRE) — Sterling Check Corp. (NASDAQ: STER) (“Sterling”), a leading global provider of background screening and identity services, today announced that it has acquired Vault Workforce Screening (“Vault”), a leading U.S. clinic management platform. The acquisition brings a network of 17,000 clinics and a flexible service model to enhance Sterling’s existing drug and health services. This will enable Sterling to deliver additional market leading screening solutions for employers in healthcare, transportation, and other regulated industries where staffing challenges are most acute, decreasing time-to-hire and improving employee retention. As part of Sterling’s strategy...

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

Written by Customer Service on January 2, 2024. Posted in Public Companies.

BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption. “In a preclinical study, we assessed the bioavailability of our collaborator’s molecule when delivered via our BioJet device in a porcine model, with comparison to subcutaneous administration. BioJet devices were administered endoscopically, which is typical in a porcine model,...

Asia Pacific Wire & Cable Corporation Limited Reports Third Quarter 2023 Financial Results

Written by Customer Service on January 2, 2024. Posted in Earnings Releases And Operating Results.

TAIPEI, Taiwan, Jan. 02, 2024 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) (“APWC” or the “Company”), a leading manufacturer of wire and cable products for the telecommunications and electric-power industries in the Asia-Pacific region, today announced the Company’s financial results for the nine months ended September 30, 2023. Unless otherwise indicated, all data are reported in U.S. Dollars at the exchange rate prevailing on the date of the event or result reported.First Nine Months 2023 Financial Results (Ended September 30, 2023), and 2022 comparative results First 9 Months 2023 First 9 Months 2022 CHANGERevenues $ 294.2 million $ 310.7 million (5.3)%Operating Profit $ 0.1 million $ 3.8 million (97.1)%Net Income $ 1.1 million $ 0.6 million 93.8%EPS1 $ 0.05 $ 0.03 66.7% Revenues...

UNISYNC Reports Fiscal 2023 Financial Results

Written by Customer Service on January 2, 2024. Posted in Earnings Releases And Operating Results.

TORONTO, Jan. 02, 2024 (GLOBE NEWSWIRE) — Unisync Corp. (“Unisync”) (TSX:”UNI”) (OTC:“USYNF”) announces its audited financial results for the fourth quarter and fiscal year ended September 30, 2023. Unisync operates through two business units: Unisync Group Limited (“UGL”) with operations throughout Canada and the USA and 90% owned Peerless Garments LP (“Peerless”), a domestic manufacturing operation based in Winnipeg, Manitoba. UGL is a leading customer-focused provider of corporate apparel, serving many leading Canadian and American iconic brands. Peerless specializes in the production and distribution of highly technical protective garments, military operational clothing, and accessories for a broad spectrum of Federal, Provincial and Municipal government departments and agencies. Results for Fiscal 2023 versus...

Coherus Announces U.S. Launch of LOQTORZI™

Written by Customer Service on January 2, 2024. Posted in Public Companies.

LOQTORZI™ (toripalimab-tpzi)LOQTORZI™ (toripalimab-tpzi) product image– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status – – LOQTORZI is now available for purchase through select specialty distributors – REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that LOQTORZI™ (toripalimab-tpzi) is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic...

urban-gro, Inc. Secures Design-Build Contract Valued at Approximately $20 Million

Written by Customer Service on January 2, 2024. Posted in Public Companies.

LAFAYETTE, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), an integrated professional services consulting firm, today announced that it has secured a design-build contract with an existing vertically integrated U.S.-based multi-state Cannabis cultivation and retail dispensary operator. The contract is for the design and construction of both a new cultivation facility and the interior retrofit of an existing facility. The contract is valued at approximately $20 million and it is anticipated that revenue will be recognized over the next six quarters. Bradley Nattrass, Chairman and CEO, commented, “Our turnkey approach coupled with our unique industry expertise allows us to streamline complex projects like this one by seamlessly integrating the design and construction phases....

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Written by Customer Service on January 2, 2024. Posted in Public Companies.

$95 million in development milestones payable over two years, as part of GSK license agreement CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years. “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an...

Branded Legacy, Inc. ($BLEG) Retires Additional 442 Million Common Shares, Surpassing Initial Commitment

Written by Customer Service on January 2, 2024. Posted in Mergers And Acquisitions.

MELBOURNE, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) — via IBN — Branded Legacy (OTC: BLEG) is further highlighting its commitment to shareholders and future growth by announcing the final retirement of an additional 442 million common shares, bringing the total shares retired to an extraordinary 2.44 billion. This action surpasses the initial commitment and signifies management’s unwavering dedication to shareholder value. This development underscores Branded Legacy’s commitment to responsible corporate governance and transparent communication with its investors. Notably, the retirements have resulted in management now owning zero common stock, aligning the company’s leadership with the best interests of its shareholders. The decision to retire an additional 442 million common shares is a testament to Branded Legacy’s...

Watsco Declares $2.45 Quarterly Dividend and Commemorates Paying Dividends for 50 Consecutive Years

Written by Customer Service on January 2, 2024. Posted in Dividend Reports And Estimates.

MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $2.45 on each outstanding share of its Common and Class B common stock payable on January 31, 2024 to shareholders of record at the close of business on January 17, 2024. Albert H. Nahmad, Watsco’s Chairman and CEO stated: “This marks our 50th consecutive year of paying dividends. We believe this represents an extraordinary milestone, especially given the Company’s strong track record of growth. We are very pleased to share our success with shareholders through dividends, which have grown at a compounded annual growth rate of 21% since Watsco entered distribution in 1989.” The Company’s philosophy is to share cash flow through dividends while maintaining a conservative balance sheet with continued...

Day: January 2, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice